Jonas Laerte Longen Junior
Research Subjects
Research Interests
Jonas Laerte Longen Junior has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alisson Carlos da Rocha
Universidade Federal de Pernambuco
1 shared publication - Alyssa Castelo Branco Alencar Andrade
Centro Universitário Christus
1 shared publication - Ana Gabriella Costa Curado
Universidade de Rio Verde
1 shared publication - Beatriz Lima da Costa
Universidade Federal do Norte do Tocantins
1 shared publication - Bruna Bezerra Pimentel Andrade
Universidade Federal de Pernambuco
1 shared publication - Daniel Machado Moura
Universidade de Rio Verde
1 shared publication
Latest Publications
- Open Access
- 6 June 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (8)
Therapeutic potential of flavonoid-rich plants in the treatment of arterial hypertension and diabetes mellitus: focus on antioxidant role
Introduction: Chronic non-communicable diseases are the main causes of morbidity and mortality today, among them, Arterial Hypertension (SAH) and Type 2 Diabetes Mellitus (T2DM), which are responsible for a variety of systemic complications. Both conditions share, in their pathophysiology, the state of oxidative stress, justifying the possible use of antioxidant components, such as flavonoids. Objectives: To characterize and describe the therapeutic potential of the main medicinal plants of popular use, rich in flavonoid-type antioxidant constituents, in the treatment of hypertension and diabetes. Methodology: An integrative literature review study, developed from a survey in PubMed, MEDLINE and LILACS databases. Results: From the survey, the following plants used for hypertension stood out: Hibiscus sabdariffa, Allium sativum L., Phyllathus amarus, Ginkgo biloba and Matricaria chamomilla. As for diabetes, the following stand out: Syzygium cumini L., Caesalpinia sappan, Andrographis paniculata and Curcuma longa L. Conclusion: The results showed that the use of medicinal plants rich in flavonoids can serve as an important ally in the prevention, control and treatment. of SAH and T2DM, acting mainly against the state of oxidative stress, a common pathophysiological mechanism in both diseases, and thus preventing the occurrence of complications resulting from this state.
- 6 June 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (8)
Open AccessTherapeutic potential of flavonoid-rich plants in the treatment of arterial hypertension and diabetes mellitus: focus on antioxidant role
Introduction: Chronic non-communicable diseases are the main causes of morbidity and mortality today, among them, Arterial Hypertension (SAH) and Type 2 Diabetes Mellitus (T2DM), which are responsible for a variety of systemic complications. Both conditions share, in their pathophysiology, the state of oxidative stress, justifying the possible use of antioxidant components, such as flavonoids. Objectives: To characterize and describe the therapeutic potential of the main medicinal plants of popular use, rich in flavonoid-type antioxidant constituents, in the treatment of hypertension and diabetes. Methodology: An integrative literature review study, developed from a survey in PubMed, MEDLINE and LILACS databases. Results: From the survey, the following plants used for hypertension stood out: Hibiscus sabdariffa, Allium sativum L., Phyllathus amarus, Ginkgo biloba and Matricaria chamomilla. As for diabetes, the following stand out: Syzygium cumini L., Caesalpinia sappan, Andrographis paniculata and Curcuma longa L. Conclusion: The results showed that the use of medicinal plants rich in flavonoids can serve as an important ally in the prevention, control and treatment. of SAH and T2DM, acting mainly against the state of oxidative stress, a common pathophysiological mechanism in both diseases, and thus preventing the occurrence of complications resulting from this state.
- Open Access
- 14 May 2022
- Published by e-Academica in E-Acadêmica
- Vol. 3 (2) , e6232206
O agravamento das doenças reumáticas pós Covid 19: uma revisão integrativa
Introduction: COVID-19 is a disease caused by the new coronavirus, called SARS-CoV-2, an RNA virus, which initially emerged in Wuhan, China, in December 2019. asymptomatic and severe conditions, especially in patients with previous pathologies, such as patients with rheumatologic diseases. Method: The work was carried out in the form of an integrative review of the literature, it aimed to bring together the studies and identify the possible complications that rheumatic diseases would have in patients who contract COVID-19. Results/Discurssion: In view of the current health situation, the analysis of the studies showed that both COVID-19 and rheumatic diseases present a pathogenic cytokine, among the diseases rheumatoid arthritis, lupus erythematosus and primary Sjogren's spindrome. Conclusion: The work presented difficulties during its production, the greatest difficulty was the lack of literature that addresses the subject. Therefore, patients with DRIM must be evaluated individually and dimensioned for each clinical situation, especially in situations where COVID is suspected, in these cases the rheumatologist has a fundamental role in decision-making.
- 14 May 2022
- Published by e-Academica in E-Acadêmica
- Vol. 3 (2) , e6232206
Open AccessO agravamento das doenças reumáticas pós Covid 19: uma revisão integrativa
Introduction: COVID-19 is a disease caused by the new coronavirus, called SARS-CoV-2, an RNA virus, which initially emerged in Wuhan, China, in December 2019. asymptomatic and severe conditions, especially in patients with previous pathologies, such as patients with rheumatologic diseases. Method: The work was carried out in the form of an integrative review of the literature, it aimed to bring together the studies and identify the possible complications that rheumatic diseases would have in patients who contract COVID-19. Results/Discurssion: In view of the current health situation, the analysis of the studies showed that both COVID-19 and rheumatic diseases present a pathogenic cytokine, among the diseases rheumatoid arthritis, lupus erythematosus and primary Sjogren's spindrome. Conclusion: The work presented difficulties during its production, the greatest difficulty was the lack of literature that addresses the subject. Therefore, patients with DRIM must be evaluated individually and dimensioned for each clinical situation, especially in situations where COVID is suspected, in these cases the rheumatologist has a fundamental role in decision-making.